King's College London

Research portal

Outcome measurement in functional neurological disorder: a systematic review and recommendations.

Research output: Contribution to journalReview article

Susannah Pick, David Anderson, Ali Asadi-Pooya, Selma Aybek, Gaston Baslet, Bastiaan R. Bloem, Abigail Bradley-Westguard, Richard J Brown, Alan J. Carson, Trudie Chalder, Maria Damianova, Anthony Sion David, Mark J. Edwards, Steven A Epstein, Alberto J. Espay, Beatrice Garcin, Laura Hilary Goldstein, Mark Hallett, Joseph Jankovic, Eileen Joyce & 26 more Richard A. Kanaan, Roxanne Christina Keynejad, Kasia Kozlowska, Kathrin LaFaver, W. Curt Lafrance, Anthony E Lang, Alexander Lehn, Sarah Lidstone, Carine Maurer, Bridget Mildon, Francesca Morgante, Lorna Myers, Clare Nicholson, Glenn Nielsen, David Perez, Stoyan Popkirov, Markus Reuber, Karen Rommelfanger, Petra Schwingenshuh, Tereza Serranova, Paul Shotbolt, Glenn T. Stebbins, Jon Stone, Marina A.J. Tijssen, Michele Tinazzi, Timothy Richard Joseph Nicholson

Original languageEnglish
JournalJournal of Neurology, Neurosurgery and Psychiatry
Publication statusAccepted/In press - 19 Dec 2019


King's Authors


Objective: We aimed to identify existing outcome measures for functional neurological disorder (FND), to inform the development of recommendations and guide future research on FND outcomes.
Method: A systematic review was conducted to identify existing FND-specific outcome measures and the most common measurement domains and measures in previous treatment studies. Searches of Embase, Medline, and PsycINFO were conducted between January 1965 and June 2019. The findings were discussed during two international meetings of the FND-Core Outcome Measures group.
Results: Five FND-specific measures were identified - three clinician-rated and two patient-rated, but their measurement properties have not been rigorously evaluated. No single measure was identified for use across the range of FND symptoms in adults. Across randomised controlled trials (k=40) and observational treatment studies (k=40), outcome measures most often assessed core FND symptom change. Other domains measured commonly were additional physical and psychological symptoms, life impact (i.e., quality of life, disability, general functioning) and health economics/cost-utility (e.g., healthcare resource utilisation, quality adjusted life years).
Conclusions: There are few well-validated FND-specific outcome measures. Thus, at present we recommend that existing outcome measures, known to be reliable, valid and responsive in FND or closely related populations, are used to capture key outcome domains. Increased consistency in outcome measurement will facilitate comparison of treatment effects across FND symptom types and treatment modalities. Future work needs to more rigorously validate outcome measures used in this population.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454